Recombinant Human KRAS Protein，HEK293

KRAS is a prominent oncogene that plays a crucial role in cell signaling pathways regulating cell growth and differentiation. Mutations in KRAS are frequently associated with various cancers, including pancreatic, colorectal, and lung cancers, making it a significant target for cancer research and therapy. The KRAS protein acts as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state, thus influencing downstream signaling pathways like the MAPK and PI3K-Akt pathways. Understanding the structure and function of recombinant KRAS proteins is vital for elucidating the mechanisms of oncogenesis and for the development of targeted therapies. Recent advances in molecular biology techniques have allowed for the successful expression and purification of recombinant KRAS proteins, enabling researchers to study their biochemical properties, interactions with other cellular components, and the effects of specific mutations. Furthermore, the development of specific inhibitors targeting mutant KRAS variants, such as KRASG12C, has shown promise in clinical settings, underscoring the importance of continuing research in this area. This knowledge not only enhances our understanding of cancer biology but also paves the way for novel therapeutic strategies aimed at disrupting the pathological signaling pathways activated by mutated KRAS, ultimately improving treatment outcomes for patients with KRAS-driven malignancies.